Pre-clinical studies in animal models, including imiquimod-induced psoriasis (21), spontaneous colonic inflammation (22), antigen induced arthritis (17), EAE (23), and experimental autoimmune uveitis (EAU) (24), confirmed that RORC inhibition markedly reduces local and systemic IL-17A levels and decreases tissue inflammation. The gene discussed is RORC; the disease is colitis.